Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge - 2The most effective method to Decisively Use Open Record Rewards
- 34 Excellent Remote Headphones of 2024
- 4Air travelers face higher ticket prices as Iran war drives up oil prices
- 5Astronaut on ISS captures spectacular orbital video of zodiacal light, auroras and the Pleiades
- James Webb Space Telescope discovers a lemon-shaped exoplanet unlike anything seen before: 'What the heck is this?'
- ‘Harry Potter and the Philosopher’s Stone’ trailer is raising eyebrows among Potterheads: ‘Where’s the whimsical color?’
- The Fate of Gaming: 5 Energizing Advancements Not too far off
- 4 astronauts depart ISS, leaving behind just 3 crewmates to staff the orbiting lab
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- Administrative building in Sharjah region targeted by Iranian drone, UAE authorities announce
- Manual for Vegetarian Protein Powder
- Warning for snow and ice extended
- A company is trying to unlock a key to aging, in a long-overlooked body part
